# The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Study · id `cardio:ct-nct05084235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05084235](<https://clinicaltrials.gov/study/NCT05084235>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05084235

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.

## Technical summary

Registry record NCT05084235. Randomized; quadruple masking; primary purpose prevention. Start 2021-09-02 (actual); primary completion 2025-01-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 191 participants (enrolled count; ClinicalTrials.gov record NCT05084235, source copy `cardio:ctgov-nct05084235-2025-01-29`, retrieved 2026-10-26)
- Started: 2021-09-02 (actual) (ClinicalTrials.gov record NCT05084235, source copy `cardio:ctgov-nct05084235-2025-01-29`, retrieved 2026-10-26)
- Primary completion: 2025-01-16 (actual) (ClinicalTrials.gov record NCT05084235, source copy `cardio:ctgov-nct05084235-2025-01-29`, retrieved 2026-10-26)
- Completion: 2025-01-16 (actual) (ClinicalTrials.gov record NCT05084235, source copy `cardio:ctgov-nct05084235-2025-01-29`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT05084235, source copy `cardio:ctgov-nct05084235-2025-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05084235-2025-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
- Condition: Heart Failure
- Condition: Obesity
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: Jacob Moller
- Lead sponsor class: OTHER
- Collaborator: Danish Heart Foundation
- Collaborator class: OTHER
- Collaborator: Herlev and Gentofte Hospital
- Collaborator class: OTHER
- Collaborator: University Hospital Bispebjerg and Frederiksberg
- Collaborator class: OTHER
- Collaborator: Hillerod Hospital, Denmark
- Collaborator class: OTHER
- Collaborator: Copenhagen University Hospital, Rigshospitalet
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as a collaborator: Danish Heart Foundation (`cardio:org-danish-heart-foundation`)
- Registry lists this organization as a collaborator: Herlev and Gentofte Hospital (`cardio:org-herlev-and-gentofte-hospital`)
- Registry lists this organization as a collaborator: University Hospital Bispebjerg and Frederiksberg (`cardio:org-university-hospital-bispebjerg-and-frederiksberg`)
- Registry lists this organization as a collaborator: Hillerod Hospital, Denmark (`cardio:org-hillerod-hospital-denmark`)
- Registry lists this organization as a collaborator: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)

## Provenance

Content hash: f358960c190cd6e1539b55a6114f052b050263c92e492668d492dcc98b05aa59
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
